Mike Peoples

The University of Texas MD Anderson Cancer Center — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

1h-index267citations10works1.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chromatin Remodeling and Cancer(8), Cancer Mechanisms and Therapy(8), Protein Degradation and Inhibitors(6), Neurofibromatosis and Schwannoma Cases(2), Cancer Cells and Metastasis(1)

Publications10 total

Adaptive Plasticity Tumor Cells Modulate MAPK-Targeting Therapy Response in Colorectal Cancer
2025· 1 citedOpen Access
Data from The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies
2023Open Access
Supplementary Figures 1 - 8 from The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies
2023Open Access
Supplementary Figures 1 - 8 from The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies
2023Open Access
Supplementary Methods, Figure Legends from The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies
2023Open Access
Supplementary Methods, Figure Legends from The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies
2023Open Access
Data from The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies
2023Open Access
Abstract 3528: The SMARCA2/4 catalytic activity, but not the bromodomain, is a drug target in SWI/SNF mutant cancers
Cancer Research·2015
The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies
Cancer Research·2015· 266 citedOpen Access
The effects of the phosphatase inhibitor, okadaic acid, on plasminogen activator expression in bovine oocyte-cumulus cell complexes
2003

Frequent Co-authors

Joseph R. Marszalek(9), Bhavatarini Vangamudi(8), Thomas A. Paul(8), Parantu K. Shah(8), Lisa Nottebaum(8), Xi Shi(8), Yanai Zhan(8), Elisabetta Leo(8), Harshad S. Mahadeshwar(8), Alexei Protopopov(8), P. Andrew Futreal(8), Trang N. Tieu(8), Timothy P. Heffernan(8), Carlo Toniatti(8), Alessia Petrocchi(8), Dominique Verhelle(8), Dafydd R. Owen(8), Giulio Draetta(8), Wylie S. Palmer(8), Shikhar Sharma(8)